Ftse Mib
38.009,05
-0,78%
DAX
22.567,14
-0,44%
S&P 500
5.521,52
-1,39%
NASDAQ
17.303,01
-1,96%
Bitcoin
81.086,73
-3,10%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. AMEX Can Fite BioPharma Ltd (CANF) Can Fite BioPharma Ltd (CANF) Notizie

Can Fite BioPharma Ltd

CANF
1,55
0,00 (0,00%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 22:04:38
Dati in Delay di 15 minuti
Borsa: AMEX
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
03/3/202512:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/3/202512:00GLOBECan-Fite Innovative Publication: Namodenoson in Liver Cancer..
18/2/202513:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/2/202513:00GLOBEDisappearance of Decompensated Liver Cirrhosis Episodes..
14/2/202523:33EDGAR2Form SCHEDULE 13G/A - Statement of Beneficial Ownership by..
10/2/202513:10GLOBEJoin Can-Fite’s Exclusive Live Investor Webinar and Q&A..
05/2/202513:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/2/202513:00GLOBECan-Fite BioPharma to Present the Namodenoson Anti-Obesity..
27/1/202513:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/1/202513:00GLOBEUS Patent Office Granted Can-Fite Namodenoson Patent for Use..
30/12/202413:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/12/202413:00GLOBERecognition of the American Society of Clinical Oncology..
04/12/202413:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202413:00GLOBE8 Years Survival with Complete Cure for a Patient with..
14/11/202422:48EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
11/11/202413:00GLOBECan-Fite Achieves Milestone with First Patient Dosing in..
04/11/202413:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/11/202413:08GLOBECan-Fite anti-Obesity Drug Namodenoson Received Patent..
18/10/202415:23EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/10/202415:06GLOBESignificant Positive Results from Osteoarthritis Clinical ..
09/10/202413:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/10/202413:00GLOBEFDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson..
07/10/202413:00GLOBEJoin Can-Fite’s Exclusive Live Investor Webinar and Q&A..
24/9/202413:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/9/202413:00GLOBEProjected Income of $325M to Can-Fite Over the Next 10 Years..
16/9/202413:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/9/202413:00GLOBECan-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with..
06/9/202422:30EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
30/8/202422:18EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/8/202422:18EDGAR2Form F-3 - Registration statement by foreign private issuers
30/8/202422:16EDGAR2Form POS AM - Post-Effective amendments for registration..
30/8/202422:15EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/8/202414:46EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/8/202414:15GLOBECan-Fite Reports First Half 2024 Financial Results &..
12/8/202412:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/8/202412:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/8/202401:01GLOBECan-Fite Announces Exercise of Warrants for Approximately..
29/7/202413:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/7/202413:00GLOBECan-Fite Provides Namodenoson Patent Update
17/7/202413:00GLOBEJoin Can-Fite’s Exclusive Live Investor Webinar and Q&A..
11/7/202413:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/7/202413:00GLOBECan-Fite Applies for FDA Orphan Drug Designation for..
01/7/202413:00GLOBEImprovement in Patient with Decompensated Liver Cirrhosis..
28/6/202413:00BWPositive Results from Osteoarthritis Clinical Study in Dogs..
24/6/202413:00BWCan-Fite: Breakthrough Findings Demonstrate Namodenoson..
10/6/202413:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/6/202413:00BWCan-Fite Received IRB Approval for the Treatment of..
07/6/202422:15EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
05/6/202413:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/6/202413:00BWCan-Fite Updates on its Advanced Liver Cancer Pivotal Phase..
Apertura: 1,53 Min: 1,52 Max: 1,5732
Chiusura: 1,55

La tua Cronologia

AMEX
CANF
Can Fite BioPharma
CSE
FOG.X
FogChain
TG
A28Y0U
Dell Bank International ...
USOTC
CSTXF
Cryptostar (QB)
NASDAQ
THCH
TH
FX
HKDCZK
HKD vs CZK
TG
7MN
Minesto AB
AQEU
DIAE
Distribuidora Internacio...
NYSE
CHPT
ChargePoint
LSE
BRD
Bluerock Diamonds
AMEX
BTAL
AGF US Market Neutral An...
USOTC
HRNTF
HRnetGroup (PK)
NASDAQ
CALI
BlackRock ETF Trust II i...
AQEU
COPD
CompuGroup Medical SE & ...
NASDAQ
TSLL
Direxion Daily TSLA Bull...
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci